摘要
Donanemab注射液是一种突破性Aβ靶向新药,针对抗β淀粉样蛋白的抗体药物,主要适用于早期阿尔茨海默病。临床前研究发现其能改善海马和大脑皮质层的淀粉样蛋白沉积情况,临床试验显示其能调节认知能力和日常生活活动能力方面问题。本文对Donanemab注射液目前存在的研究进行介绍,以期增强对前沿新药的认识。
Donanemab is a novel anti-amyloid antibody medication that is primarily used to treat early-stage symptomatic Alzheimer's disease.Clinical investigations have demonstrated that it modulates issues with cognitive function and everyday functioning.Preclinical research has discovered that it reduces amyloid deposition in the hippocampus and cortical layers of the brain.To better comprehend cutting-edge novel medications,this article examines the latest research on donanemab.
作者
敖日格勒宝力高
万全
白国柱
呼格吉乐巴图
AO Ri-ge-le-bao-li-gao;WAN Quan;BAI Guo-zhu;HU Ge-ji-le-ba-tu(Integrated Chinese and Western Medicine General Surgery,Affiliated Hospital of Inner Mongolia University for Nationalities,Tongliao 028000,Inner Mongolia,China;Integrated Chinese and Western Medicine Cardiovascular Disease Medicine,Affiliated Hospital of Inner Mongolia University for Nationalities,Tongliao 028000,Inner Mongolia,China;Integrated Chinese and Western Medicine Encephalopathy,Affiliated Hospital of Inner Mongolia University for Nationalities,Tongliao 028000,Inner Mongolia,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2024年第9期1372-1374,共3页
The Chinese Journal of Clinical Pharmacology
基金
内蒙古自治区蒙医药标准化项目基金资助项目(2022 MB015)。
